Athenex (ATNX) Getting Somewhat Favorable Press Coverage, Study Finds
News coverage about Athenex (NASDAQ:ATNX) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Athenex earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.1440143696783 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Athenex (ATNX) opened at 17.43 on Tuesday. Athenex has a one year low of $11.21 and a one year high of $20.79. The company’s 50-day moving average is $16.37 and its 200-day moving average is $16.46. The stock’s market capitalization is $994.61 million.
Athenex (NASDAQ:ATNX) last announced its earnings results on Monday, August 14th. The company reported ($0.88) EPS for the quarter. The firm had revenue of $4.60 million for the quarter.
Separately, Deutsche Bank AG initiated coverage on shares of Athenex in a report on Monday, July 10th. They set a “buy” rating and a $20.00 price target on the stock.
ILLEGAL ACTIVITY WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/12/athenex-atnx-getting-somewhat-favorable-press-coverage-study-finds.html.
In other news, Director Song-Yi Zhang acquired 328,637 shares of the company’s stock in a transaction on Monday, June 19th. The shares were bought at an average cost of $11.00 per share, with a total value of $3,615,007.00. Following the purchase, the director now owns 4,000 shares of the company’s stock, valued at approximately $44,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Johnson Yiu Nam Lau acquired 25,200 shares of the company’s stock in a transaction on Monday, June 19th. The stock was purchased at an average cost of $11.00 per share, for a total transaction of $277,200.00. Following the completion of the purchase, the chief executive officer now directly owns 2,722,722 shares in the company, valued at approximately $29,949,942. The disclosure for this purchase can be found here.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Stock Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related stocks with our FREE daily email newsletter.